Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax

Trends in Parasitology

Volumn 28, Issue 11, 2012, Pages 522-529

  Price, Ric N ^a,b   Auburn, Sarah ^a   Marfurt, Jutta ^a   Cheng, Qin ^c,d  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Chloroquine; Clinical trials; Drug resistance; Genotyping; In vitro drug susceptibility test; Malaria; Molecular markers; Plasmodium vivax

Indexed keywords

BIOLOGICAL MARKER; CHLOROQUINE; FOLIC ACID ANTAGONIST; MEFLOQUINE; PIPERAQUINE; PRIMAQUINE;

CLINICAL TRIAL (TOPIC); DRUG SENSITIVITY; DRUG TREATMENT FAILURE; EX VIVO STUDY; GENE SEQUENCE; GENOTYPE; HUMAN; IN VIVO STUDY; MORPHOLOGICAL TRAIT; NONHUMAN; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; RECURRENT INFECTION; REVIEW;

ANTIMALARIALS; BIOLOGICAL MARKERS; DRUG RESISTANCE; GENOTYPE; MALARIA; PHENOTYPE; PLASMODIUM VIVAX;

PLASMODIUM VIVAX;

EID: 84867891053     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2012.08.005     Document Type: Review

References (90)

1. Berliner R.W., et al. A Survey of Antimalarial Drugs, 1941-1945 1946, Edwards. F.Y. Wiseogle (Ed.).
2. Rieckmann K.H., et al. Plasmodium vivax resistance to chloroquine?. Lancet 1989, 2:1183-1184.
3. Baird J.K., et al. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am. J. Trop. Med. Hyg. 1991, 44:547-552.
4. Baird, J.K. et al. Diagnosis and treatment of Plasmodium vivax malaria. Adv. Parasitol. (in press).
5. Price R.N., et al. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg. 2007, 77:79-87.
6. Poespoprodjo J.R., et al. Vivax malaria: a major cause of morbidity in early infancy. Clin. Infect. Dis. 2009, 48:1704-1712.
7. Poespoprodjo J.R., et al. Adverse pregnancy outcomes in an area where multidrug-resistant Plasmodium vivax and Plasmodium falciparum infections are endemic. Clin. Infect. Dis. 2008, 46:1374-1381.
8. Poespoprodjo J.R., et al. Severe congenital malaria acquired in utero. Am. J. Trop. Med. Hyg. 2010, 82:563-565.
9. Anstey N.M., et al. The pathophysiology of vivax malaria. Trends Parasitol. 2009, 25:220-227.
10. Tjitra E., et al. Multidrug-resistant Plasmodium vivax Associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 2008, 5:e128.
11. Genton B., et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med. 2008, 5:e127.
12. Sumawinata I.W., et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and Plasmodium falciparum malaria in Indonesian Papua. Am. J. Trop. Med. Hyg. 2003, 68:416-420.
13. Ratcliff A., et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans. R. Soc. Trop. Med. Hyg. 2007, 101:351-359.
14. Karunajeewa H.A., et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N. Engl. J. Med. 2008, 359:2545-2557.
15. Price R.N., et al. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr. Opin. Infect. Dis. 2009, 22:430-435.
16. Douglas N.M., et al. Artemisinin combination therapy for vivax malaria. Lancet Infect. Dis. 2010, 10:405-416.
17. World Health Organization and Medicines for Malaria Venture Genotyping to identify parasite populations. Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy 2008, World Health Organization. http://www.who.int/malaria/publications/atoz/9789241596305/en/.
18. Imwong M., et al. Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar. J. 2005, 4:20.
19. Chen N., et al. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J. Infect. Dis. 2007, 195:934-941.
20. Koepfli C., et al. Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J. Infect. Dis. 2009, 199:1074-1080.
21. Barnadas C., et al. Characterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers. Antimicrob. Agents Chemother. 2011, 55:4479-4481.
22. Imwong M., et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J. Infect. Dis. 2007, 195:927-933.
23. Imwong M., et al. Contrasting genetic structure in Plasmodium vivax populations from Asia and South America. Int. J. Parasitol. 2007, 37:1013-1022.
24. White N.J. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar. J. 2011, 10:297.
25. Baird J.K., et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am. J. Trop. Med. Hyg. 1997, 56:621-626.
26. White N.J. The assessment of antimalarial drug efficacy. Trends Parasitol. 2002, 18:458-464.
27. Phyo A.P., et al. Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin. Infect. Dis. 2011, 53:977-984.
28. Ratcliff A., et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007, 369:757-765.
29. Bacon D.J., et al. World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. Malar. J. 2007, 6:120.
30. Udomsangpetch R., et al. Short-term in vitro culture of field isolates of Plasmodium vivax using umbilical cord blood. Parasitol. Int. 2007, 56:65-69.
31. Golenda C.F., et al. Continuous in vitro propagation of the malaria parasite Plasmodium vivax. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:6786-6791.
32. Tasanor O., et al. Clinical-parasitological response and in-vitro sensitivity of Plasmodium vivax to chloroquine and quinine on the western border of Thailand. Trans. R. Soc. Trop. Med. Hyg. 2006, 100:410-418.
33. Russell B.M., et al. Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where Plasmodium falciparum is endemic. Antimicrob. Agents Chemother. 2003, 47:170-173.
34. Chotivanich K., et al. In vitro efficacy of antimalarial drugs against Plasmodium vivax on the western border of Thailand. Am. J. Trop. Med. Hyg. 2004, 70:395-397.
35. Druilhe P., et al. Improved assessment of Plasmodium vivax response to antimalarial drugs by a colorimetric double-site Plasmodium lactate dehydrogenase antigen capture enzyme-linked immunosorbent assay. Antimicrob. Agents Chemother. 2007, 51:2112-2116.
36. Russell B., et al. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob. Agents Chemother. 2008, 52:1040-1045.
37. Kosaisavee V., et al. Plasmodium vivax: isotopic, PicoGreen, and microscopic assays for measuring chloroquine sensitivity in fresh and cryopreserved isolates. Exp. Parasitol. 2006, 114:34-39.
38. Malleret B., et al. A rapid and robust tri-color flow cytometry assay for monitoring malaria parasite development. Sci. Rep. 2011, 1:118.
39. Congpuong K., et al. Sensitivity of Plasmodium vivax to chloroquine in Sa Kaeo Province, Thailand. Acta Trop. 2002, 83:117-121.
40. Suwanarusk R., et al. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS ONE 2007, 2:e1089.
41. Sharrock W.W., et al. Plasmodium vivax trophozoites insensitive to chloroquine. Malar. J. 2008, 7:94.
42. Kerlin D.H., et al. An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing. PLoS Negl. Trop. Dis. 2012, 6:e1772.
43. Hasugian A.R., et al. In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax. Antimicrob. Agents Chemother. 2009, 53:1094-1099.
44. Suwanarusk R., et al. Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. J. Infect. Dis. 2008, 198:1558-1564.
45. Chotivanich K., et al. Antimalarial drug susceptibility of Plasmodium vivax in the Republic of Korea. Am. J. Trop. Med. Hyg. 2009, 80:902-904.
46. Lek-Uthai U., et al. Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum. Antimicrob. Agents Chemother. 2008, 52:2435-2441.
47. Marfurt J., et al. Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and Plasmodium falciparum. Antimicrob. Agents Chemother. 2011, 55:961-966.
48. Marfurt J., et al. Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and Plasmodium falciparum. Antimicrob. Agents Chemother. 2011, 55:4461-4464.
49. Price R.N., et al. In vitro activity of pyronaridine against multidrug resistant Plasmodium falciparum and Plasmodium falciparum. Antimicrob. Agents Chemother. 2010, 51:5146-5150.
50. Marfurt J., et al. Artemisinin-based combination therapy against Plasmodium falciparum: Comparative ex vivo activity of next-generation endoperoxides in multidrug resistant field isolates. Antimicrob. Agents Chemother. 2012, 10.1128/AAC.00283-12.
51. Nomura T., et al. Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria. J. Infect. Dis. 2001, 183:1653-1661.
52. Sa J.M., et al. Expression and function of pvcrt-o, a Plasmodium vivax ortholog of pfcrt, in Plasmodium falciparum and Dictyostelium discoideum. Mol. Biochem. Parasitol. 2006, 150:219-228.
53. Barnadas C., et al. Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes. Antimicrob. Agents Chemother. 2008, 52:4233-4240.
54. Fernandez-Becerra C., et al. Increased expression levels of the pvcrt-o and pvmdr1 genes in a patient with severe Plasmodium vivax malaria. Malar. J. 2009, 8:55.
55. Marfurt J., et al. Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1. J. Infect. Dis. 2008, 198:409-417.
56. Sa J.M., et al. Plasmodium vivax: allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains. Exp. Parasitol. 2005, 109:256-259.
57. Kim Y.K., et al. Therapeutic efficacy of chloroquine in Plasmodium vivax and the pvmdr1 polymorphisms in the Republic of Korea under mass chemoprophylaxis. Am. J. Trop. Med. Hyg. 2011, 84:532-534.
58. Imwong M., et al. Gene amplification of Plasmodium vivax multidrug resistance 1 gene in Thailand, Laos, and Myanmar. Antimicrob. Agents Chemother. 2008, 52:2657-2659.
59. Auliff A., et al. Amino acid mutations in Plasmodium vivax DHFR and DHPS from several geographical regions and susceptibility to antifolate drugs. Am. J. Trop. Med. Hyg. 2006, 75:617-621.
60. Hastings M.D., et al. Novel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system. Antimicrob. Agents Chemother. 2005, 49:733-740.
61. Rungsihirunrat K., et al. Geographical distribution of amino acid mutations in Plasmodium vivax DHFR and DHPS from malaria endemic areas of Thailand. Am. J. Trop. Med. Hyg. 2008, 78:462-467.
62. Zakeri S., et al. Molecular characterization of antifolates resistance-associated genes, (dhfr and dhps) in Plasmodium vivax isolates from the Middle East. Malar. J. 2009, 8:20.
63. Tjitra E., et al. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob. Agents Chemother. 2002, 46:3947-3953.
64. Auliff A.M., et al. Defining the role of mutations in Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium falciparum transfection system. Antimicrob. Agents Chemother. 2010, 54:3927-3932.
65. O'Neil M.T., et al. A novel Plasmodium falciparum expression system for assessing antifolate resistance caused by mutant Plasmodium falciparum dihydrofolate reductase-thymidylate synthase. J. Infect. Dis. 2007, 196:467-474.
66. Auliff A.M., et al. Functional analysis of Plasmodium vivax dihydrofolate reductase-thymidylate synthase genes through stable transformation of Plasmodium falciparum. PLoS ONE 2012, 7:e40416.
67. Imwong M., et al. Limited polymorphism in the dihydropteroate synthetase gene (dhps) of Plasmodium vivax isolates from Thailand. Antimicrob. Agents Chemother. 2005, 49:4393-4395.
68. Carter R., et al. Linkage Group Selection - a fast approach to the genetic analysis of malaria parasites. Int. J. Parasitol. 2007, 37:285-293.
69. Hunt P., et al. Experimental evolution, genetic analysis and genome re-sequencing reveal the mutation conferring artemisinin resistance in an isogenic lineage of malaria parasites. BMC Genomics 2010, 11:499.
70. Auburn S., et al. An effective method to purify Plasmodium falciparum DNA directly from clinical blood samples for whole genome high-throughput sequencing. PLoS ONE 2011, 6:e22213.
71. Mu J., et al. Recent progress in functional genomic research in Plasmodium falciparum. Curr. Genomics 2010, 11:279-286.
72. Park D.J., et al. Sequence-based association and selection scans identify drug resistance loci in the Plasmodium falciparum malaria parasite. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:13052-13057.
73. Van Tyne D., et al. Identification and functional validation of the novel antimalarial resistance locus PF10_0355 in Plasmodium falciparum. PLoS Genet. 2011, 7:e1001383.
74. Sabeti P.C., et al. Detecting recent positive selection in the human genome from haplotype structure. Nature 2002, 419:832-837.
75. Amambua-Ngwa A., et al. SNP genotyping identifies new signatures of selection in a deep sample of West African Plasmodium falciparum Malaria Parasites. Mol. Biol. Evol. 2012, 10.1093/molbev/mss151.
76. Sabeti P.C., et al. Genome-wide detection and characterization of positive selection in human populations. Nature 2007, 449:913-918.
77. Dharia N.V., et al. Whole-genome sequencing and microarray analysis of ex vivo Plasmodium vivax reveal selective pressure on putative drug resistance genes. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:20045-20050.
78. Sriprawat K., et al. Effective and cheap removal of leukocytes and platelets from Plasmodium vivax infected blood. Malar. J. 2009, 8:115.
79. Bright A.T., et al. Whole genome sequencing analysis of Plasmodium vivax using whole genome capture. BMC Genomics 2012, 13:262.
80. Manske M., et al. Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature 2012, 10.1038/nature11174.
81. Carlton J.M., et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature 2008, 455:757-763.
82. Neafsey D.E., et al. The malaria parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium falciparum. Nat. Genet. 2012, 10.1038/ng.2373.
83. Ferreira M.U., et al. Population structure and transmission dynamics of Plasmodium vivax in rural Amazonia. J. Infect. Dis. 2007, 195:1218-1226.
84. Karunaweera N.D., et al. Extensive microsatellite diversity in the human malaria parasite Plasmodium vivax. Gene 2008, 410:105-112.
85. Orjuela-Sanchez P., et al. Single-nucleotide polymorphism, linkage disequilibrium and geographic structure in the malaria parasite Plasmodium vivax: prospects for genome-wide association studies. BMC Genet. 2010, 11:65.
86. Baird J.K. Neglect of Plasmodium vivax malaria. Trends Parasitol. 2007, 23:533-539.
87. Mueller I., et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect. Dis. 2009, 9:555-566.
88. Brega S., et al. Identification of the Plasmodium vivax mdr-like gene (pvmdr1) and analysis of single-nucleotide polymorphisms among isolates from different areas of endemicity. J. Infect. Dis. 2005, 191:272-277.
89. Korsinczky M., et al. Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site. Antimicrob. Agents Chemother. 2004, 48:2214-2222.
90. Siswantoro H., et al. In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. Antimicrob. Agents Chemother. 2011, 55:197-202.